Anti-viral Therapeutics Market,Share Size and Forecast 2019-2026

SKU: DHC255 | Last Updated On: Sep 20 2019 | No. of Pages: 189 | Available Formats

In April 2019, the US FDA approved Dovato for the treatment of HIV-1 infection in adults to ViiV Healthcare.

Market Overview

The Global Anti-viral Therapeutics market was valued at USD XX million in 2018 and expected to grow at a CAGR of XX% to reach a market value of USD XX million by 2026.

 

Antiviral drugs are a class of medication, which are used in treating viral infections, and most antivirals are used for specific viral infections. Antiviral drugs are sold prescription-based only and are different from antibiotics, which fight against bacterial infections. Unlike most antibiotics, antiviral medication does not destroy the target pathogen, but instead, they obstruct the development. Most antiviral drugs currently available are to help deal with herpes viruses, HIV, influenza A, and B viruses, and hepatitis B, and C viruses. Moreover, researchers are working on expanding the range of antivirals to other families of pathogens.

Market Dynamics

The global market for the Antiviral Therapeutics The market is primarily driven by the growing incidents of viral infections among populations. According to UNAIDS, in 2017, there were an estimated 36.9 million people [31.1 million–43.9 million] worldwide living with HIV/AIDS, of which 1.8 million were children (15 years old and below), and an estimated 1.8 million individuals became newly infected with HIV. According to the World Health Organization (WHO), an estimated 257 million people are living with hepatitis B virus infection, and in 2015, hepatitis B resulted in 887 000 deaths. WHO estimated that 71 million people are infected with hepatitis C worldwide. Moreover, strong R&D, increasing product launches, a strong pipeline for antiviral drugs coupled with the increasing awareness on viral infections and their treatments are of the key drivers in the antiviral therapeutics market growth. For instance, in May 2019, Atriva Therapeutics GmbH announced the first dose up of its lead drug candidate ATR-002 in a Phase I clinical trial, marks the start of the clinical development of a novel host-targeted approach to treating influenza virus infections. However, the patent expiration of blockbuster drugs and the high cost of Antiviral therapeutics may hinder market progress.   

 

Market Segmentation

By Application, the Global Antiviral Therapeutics Market is segmented into HIV, Hepatitis, Herpes Simplex Virus, Influenza, and others. The HIV application holds the largest market share owing to its growing prevalence worldwide and an increasing number of drug launches coupled with several drugs currently in the pipeline. According to UNAIDS, in 2017, there were approximately 1.8 million people [1.4 million–2.4 million] who became newly infected with HIV worldwide and nearly 21.7 million people of the total 36.9 million people living with HIV/AIDS were receiving antiretroviral therapy. For instance, in 2018 alone, there were four drugs (Trogarzo, Biktarvy, Delstrigo, and Symtuza) approved by the FDA for the treatment of HIV. However, Hepatitis application is anticipated to show significant market growth, increasing R&D expenditure by key players, and approval of combination antiviral therapies. For instance, in May 2019, Cocrystal Pharma Inc., a clinical stage biotechnology company discovering and developing novel antiviral therapeutics, begun patient enrolment in its Phase 2a open-label study. The study will evaluate the safety, tolerability, and preliminary efficacy of Cocrystal’s CC-31244 in combination with Daclatasvir and Sofosbuvir with and without protease inhibitors, for the treatment of hepatitis C.

 

By Mechanism of Action, the Global Antiviral Therapeutics Market is segmented into Nucleotide Polymerase Inhibitors, Reverse Transcriptase Inhibitors, Protease Inhibitors, and others. The Reverse Transcriptase Inhibitor segment held the most significant market share owing to its high demand and broad product range for the treatment of HIV.

 

Geographical Analysis

North America accounts for the largest share in the global Antiviral Therapeutics market and is mainly attributed to the growing prevalence of HIV, Hepatitis infections, and Influenza in the region. According to the CDC in 2016, an estimated 38,700 people became newly infected with HIV in the US, and approximately 1.1 million people in the US are living with HIV. CDC reported a total of 3,218 cases of acute hepatitis B, with an overall incidence rate of 1.0 cases per 100,000 population in 2016 and CDC estimates that 800,000 to 2.2 million people in the United States have chronic hepatitis B. Moreover, the advanced regional healthcare infrastructure, high level of drug development, presence of established market players, rise in healthcare expenditure, and high investment in R&D activities by them are likely to boost the North America Antiviral Therapeutics market growth.

Competitive Analysis

Several key companies have adopted merger and acquisitions policies, geographic expansion, and collaborations to help them to stand out as strong competitors in the market and also expand its sales in the global Anti-viral Therapeutics market. Moreover, the increasing FDA approvals, product launches, and robust pipeline are improving key players’ market presence.

 

Major Players in the global Anti-viral Therapeutics market include Roche, Gilead Sciences, GlaxoSmithKline, Bristol-Myers Squibb, Johnson & Johnson and Merck.

 

In June 2019, Cidara Therapeutics Inc., a biotechnology company developing novel anti-infectives including immunotherapies, announced that new data from studies of CB-012, its Cloudbreak antiviral Fc-conjugate (AVC) candidate for influenza. CB-012 is the first AVC candidate generated by Cidara’s Cloudbreak anti-infective immunotherapy platform.

 

In April 2019, the US FDA approved Dovato (dolutegravir and lamivudine), as a complete regimen for the treatment of HIV-1 infection in adults with no antiretroviral treatment history and with no known or suspected substitutions associated with resistance to the individual components of Dovato. This is the first FDA-approved two-drug, FDC regimen for HIV-infected adults who have never received treatment for HIV.

 

FDA approvals in 2018:

  • Approved in February - Biktarvy by Gilead for the treatment of HIV-1 infection in adults.
  • Approved in August – Delstrigo by Merck for the treatment of HIV-1 infection.
  • Approved in July – Symtuza by Janssen Therapeutics for the treatment of HIV-1 infection.
  • Approved in March – Trogarzo by TaiMed Biologics for the treatment of multidrug-resistant HIV-1 infection.
  • Approved in December – Vaxelis by Merck for the prevention of diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, and Haemophilus influenzae type b.
  • Approved in October - Xofluza by Shionogi for the treatment of acute uncomplicated influenza. This is the first new anti-flu medication in nearly two decades. The FDA granted the approval to a Japanese pharmaceutical company, Shionogi & Co, and it will be distributed in the U.S. by Genentech.

 

Market Taxonomy:

On the bases of Mechanism of Action, the global Anti-viral Therapeutics market is segmented into:

  • Nucleotide Polymerase Inhibitors
  • Reverse Transcriptase Inhibitors
  • Protease Inhibitors
  • Others

 

On the bases of application, the global Anti-viral Therapeutics market is segmented into:

  • HIV
  • Hepatitis
  • Herpes Simplex Virus
  • Influenza
  • Others   

 

On the bases of Distribution Channel, the global Anti-viral Therapeutics market is segmented into:

  • Hospital Pharmacies
  • Retail Pharmacies
  • E-commerce

 

On the bases of region, the global Anti-viral Therapeutics market is segmented into:

  • North America   
  • South America
  • Europe
  • Asia Pacific
  • Middle East & Africa

 

Key Takeaways:

  • The global market for the Antiviral Therapeutics Market is primarily driven by the growing incidents of viral infections among populations. Moreover, strong R&D, increasing product launches, a strong pipeline for antiviral drugs coupled with the increasing awareness on viral infections and their treatments are of the key drivers in the antiviral therapeutics market growth.
  • The HIV application holds the largest market share owing to its growing prevalence worldwide and an increasing number of drug launches coupled with several drugs currently in the pipeline.
  • North America accounts for the largest share in the global Antiviral Therapeutics market and it mainly attributed to the growing prevalence of HIV, Hepatitis infections, and Influenza in the region.
  • The increasing FDA approvals, product launches, and robust pipeline are improving key players’ market presence. For instance, in May 2019, Cocrystal Pharma Inc., a clinical stage biotechnology company discovering and developing novel antiviral therapeutics, announced that it had begun patient enrolment in its Phase 2a open-label study. The study will evaluate the safety, tolerability, and preliminary efficacy of Cocrystal’s CC-31244 in combination with Sofosbuvir and Daclatasvir with or without a protease inhibitor, for the treatment of hepatitis C.

 

Why Purchase the Report?

  • Visualize the composition of the global Anti-viral Therapeutics Market across each indication, in terms of Type and Application options, highlighting the key commercial assets and players.
  • Identify commercial opportunities in global Anti-viral Therapeutics Market by analyzing trends and co-development deals.
  • Excel data sheet with thousands of data points of the global Anti-viral Therapeutics Market - level 4/5 segmentation.
  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
  • Type mapping in excel for the key Services of all major market players

 

Target Audience:

  • Equipment Suppliers/ Buyers
  • Type Providers/ Buyers
  • Industry Investors/Investment Bankers
  • Education & Research Institutes
  • Research Professionals
  • Emerging Companies
  • Manufacturers

1. Global Anti-viral Therapeutics Market -Scope and Methodology

1.1. Research Methodology

1.2. Scope of the market

2. Global Anti-viral Therapeutics Market -Key Trends and Developments

2.1. Key Trends and Developments

3. Global Anti-viral Therapeutics Market – Executive Summary

3.1. Market Snippet By Mechanism of Action

3.2. Market Snippet By Application

3.3. Market Snippet By Distribution Channel

3.4. Market Snippet By Region

3.5. DataM CLO Scenario

4. Global Anti-viral Therapeutics Market  Dynamics

4.1. Market impacting factors

4.2. Drivers

4.2.1. Growing Prevalence of Target Diseases

4.2.2. Strong Pipeline for Antiviral Drugs

4.2.3. Driver 3

4.3. Restraints

4.3.1. High Cost of Deployment

4.3.2. High Cost of Antiviral Drug Treatment

4.3.3. Restraint 3

4.4. Opportunity

4.5. Impact analysis

5. Global Anti-viral Therapeutics Market – Industry Analysis

5.1. Porter's five forces analysis

5.2. Supply chain analysis

5.3. Pricing analysis

5.4. Regulatory analysis

5.5. Patent analysis

6. Global Anti-viral Therapeutics Market – By Mechanism of Action

6.1. Introduction

6.2. Market size analysis, and y-o-y growth analysis (%), By Mechanism of Action segment

6.3. Market attractiveness index, By Mechanism of Action segment

6.4. Nucleotide Polymerase Inhibitors

6.4.1. Introduction

6.4.2. Market size analysis, and y-o-y growth analysis (%)

6.5. Reverse Transcriptase Inhibitors

6.6. Protease Inhibitors

6.7. Others

7. Global Anti-viral Therapeutics Market – By Application

7.1. Introduction

7.2. Market size analysis, and y-o-y growth analysis (%), By Application segment

7.3. Market attractiveness index, By Application segment

7.4. HIV

7.4.1. Introduction

7.4.2. Market size analysis, y-o-y growth analysis (%)

7.5. Hepatitis

7.6. Herpes Simplex Virus

7.7. Influenza

7.8. Others

8. Global Anti-viral Therapeutics Market – By Distribution Channel

8.1. Introduction

8.2. Market size analysis, and y-o-y growth analysis (%), By Distribution Channel segment

8.3. Market attractiveness index, By Distribution Channel segment

8.4. Hospital Pharmacies

8.4.1. Introduction

8.4.2. Market size analysis, y-o-y growth analysis (%)

8.5. Retail Pharmacies

8.6. E-commerce

9. Global Anti-viral Therapeutics Market – By Region

9.1. Introduction

9.2. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Region

9.3. Market Attractiveness Index, By Region

9.4. North America

9.4.1. Introduction

9.4.2. Key region-specific dynamics

9.4.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Mechanism of Action

9.4.4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Application

9.4.5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Distribution Channel

9.4.6. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Countries

9.4.6.1.          U.S.

9.4.6.2.         Canada

9.4.6.3.         Mexico

9.5. Europe

9.5.1. Introduction

9.5.2. Key Region-Specific Dynamics

9.5.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Mechanism of Action

9.5.4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Application

9.5.5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Distribution Channel

9.5.6. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Countries

9.5.6.1.          Germany

9.5.6.2.         U.K.

9.5.6.3.         France

9.5.6.4.         Italy

9.5.6.5.         Spain

9.5.6.6.         Rest of Europe

9.6. South America

9.6.1. Introduction

9.6.2. Key Region-Specific Dynamics

9.6.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Mechanism of Action

9.6.4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Application

9.6.5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Distribution Channel

9.6.6. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Countries

9.6.6.1.          Brazil

9.6.6.2.         Argentina

9.6.6.3.         Rest of South America

9.7. Asia Pacific

9.7.1. Introduction

9.7.2. Key Region-Specific Dynamics

9.7.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Mechanism of Action

9.7.4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Application

9.7.5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Distribution Channel

9.7.6. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Countries

9.7.6.1.          China

9.7.6.2.         India

9.7.6.3.         Japan

9.7.6.4.         Australia

9.7.6.5.         Rest of Asia Pacific

9.8. The Middle East And Africa

9.8.1. Introduction

9.8.2. Key Region-Specific Dynamics

9.8.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Mechanism of Action

9.8.4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Application

9.8.5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Distribution Channel

10. Global Anti-viral Therapeutics Market – Competitive Landscape

10.1. Competitive scenario

10.2. Competitor strategy analysis

10.3. Comparative type portfolio analysis

10.4. Market positioning/share analysis

10.5. Mergers and acquisitions analysis

11. Company Profiles

11.1. F. Hoffmann-La Roche

11.1.1. Company Overview

11.1.2. Type Portfolio And Description

11.1.3. Key Highlights

11.1.4. Financial Overview

11.2. Gilead Sciences

11.3. GlaxoSmithKline

11.4. Bristol-Myers Squibb

11.5. Johnson & Johnson

11.6. Merck & Co.

11.7. AbbVie Inc.

11.8. Abbott Laboratories

11.9. AstraZeneca plc.

11.10. Pfizer Inc.

11.11. Cipla Inc.

12. Global Anti-viral Therapeutics Market – Premium Insights

13. Global Anti-viral Therapeutics Market – DataM

13.1. Appendix

13.2. About us and services

13.3. Contact Us

 

LIST OF TABLES

Table 1 Global Periodontal Therapeutics Market Value, By Mechanism of Action, 2018,2022 & 2026 ($ Million)

Table 2 Global Periodontal Therapeutics Market Value, By Application, 2018,2022 & 2026 ($ Million)

Table 3 Global Periodontal Therapeutics Market Value, By Distribution Channel, 2018,2022 & 2026 ($ Million)

Table 4 Global Periodontal Therapeutics Market Value, By Region, 2018,2022 & 2026 ($ Million)

Table 5 Global Periodontal Therapeutics Market Value, By Mechanism of Action, 2018,2022 & 2026 ($ Million)

Table 6 Global Periodontal Therapeutics Market Value, By Mechanism of Action, 2017-2026 ($ Million)

Table 7 Global Periodontal Therapeutics Market Value, By Application, 2018,2022 & 2026 ($ Million)

Table 8 Global Periodontal Therapeutics Market Value, By Application, 2017-2026 ($ Million)

Table 9 Global Periodontal Therapeutics Market Value, By Distribution Channel, 2018,2022 & 2026 ($ Million)

Table 10 Global Periodontal Therapeutics Market Value, By Distribution Channel, 2017-2026 ($ Million)

Table 11 Global Periodontal Therapeutics Market Value, By Region, 2018,2022 & 2026 ($ Million)

Table 12 Global Periodontal Therapeutics Market Value, By Region, 2017-2026 ($ Million)

Table 13 North America Periodontal Therapeutics Market Value, By Mechanism of Action, 2017-2026 ($ Million)

Table 14 North America Periodontal Therapeutics Market Value, By Application, 2017-2026 ($ Million)

Table 15 North America Periodontal Therapeutics Market Value, By Distribution Channel, 2017-2026 ($ Million)

Table 16 North America Periodontal Therapeutics Market Value, By Country, 2017-2026 ($ Million)

Table 17 South America Periodontal Therapeutics Market Value, By Mechanism of Action, 2017-2026 ($ Million)

Table 18 South America Periodontal Therapeutics Market Value, By Application, 2017-2026 ($ Million)

Table 19 South America Periodontal Therapeutics Market Value, By Distribution Channel, 2017-2026 ($ Million)

Table 20 South America Periodontal Therapeutics Market Value, By Country, 2017-2026 ($ Million)

Table 21 Europe Periodontal Therapeutics Market Value, By Mechanism of Action, 2017-2026 ($ Million)

Table 22 Europe Periodontal Therapeutics Market Value, By Application, 2017-2026 ($ Million)

Table 23 Europe Periodontal Therapeutics Market Value, By Distribution Channel, 2017-2026 ($ Million)

Table 24 Europe Periodontal Therapeutics Market Value, By Country, 2017-2026 ($ Million)

Table 25 Asia-Pacific Periodontal Therapeutics Market Value, By Mechanism of Action, 2017-2026 ($ Million)

Table 26 Asia-Pacific Periodontal Therapeutics Market Value, By Application, 2017-2026 ($ Million)

Table 27 Asia-Pacific Periodontal Therapeutics Market Value, By Distribution Channel, 2017-2026 ($ Million)

Table 28 Asia-Pacific Periodontal Therapeutics Market Value, By Country, 2017-2026 ($ Million)

Table 29 Middle East & Africa Periodontal Therapeutics Market Value, By Mechanism of Action, 2017-2026 ($ Million)

Table 30 Middle East & Africa Periodontal Therapeutics Market Value, By Application, 2017-2026 ($ Million)

Table 31 Middle East & Africa Periodontal Therapeutics Market Value, By Distribution Channel, 2017-2026 ($ Million)

Table 32 F. Hoffmann-La Roche: Overview

Table 33 F. Hoffmann-La Roche: Product Portfolio

Table 34 F. Hoffmann-La Roche: Key Developments

Table 35 Gilead Sciences: Overview

Table 36 Gilead Sciences: Product Portfolio

Table 37 Gilead Sciences: Key Developments

Table 38 GlaxoSmithKline: Overview

Table 39 GlaxoSmithKline: Product Portfolio

Table 40 GlaxoSmithKline: Key Developments

Table 41 Bristol-Myers Squibb: Overview

Table 42 Bristol-Myers Squibb: Product Portfolio

Table 43 Bristol-Myers Squibb: Key Developments

Table 44 Johnson & Johnson: Overview

Table 45 Johnson & Johnson: Product Portfolio

Table 46 Johnson & Johnson: Key Developments

Table 47 Merck & Co.: Overview

Table 48 Merck & Co.: Product Portfolio

Table 49 Merck & Co.: Key Developments

Table 50 AbbVie Inc.: Overview

Table 51 AbbVie Inc.: Product Portfolio

Table 52 AbbVie Inc.: Key Developments

Table 53 Abbott Laboratories: Overview

Table 54 Abbott Laboratories: Product Portfolio

Table 55 Abbott Laboratories: Key Developments

Table 56 AstraZeneca plc: Overview

Table 57 AstraZeneca plc: Product Portfolio

Table 58 AstraZeneca plc: Key Developments

Table 59 Pfizer Inc.: Overview

Table 60 Pfizer Inc.: Product Portfolio

Table 61 Pfizer Inc.: Key Developments

LIST OF FIGURES

Figure 1 Global Periodontal Therapeutics Market Share, By Mechanism of Action, 2018 & 2026 (%)

Figure 2 Global Periodontal Therapeutics Market Share, By Application, 2018 & 2026 (%)

Figure 3 Global Periodontal Therapeutics Market Share, By Distribution Channel, 2018 & 2026 (%)

Figure 4 Global Periodontal Therapeutics Market Share, By Region, 2018 & 2026 (%)

Figure 5 Global Periodontal Therapeutics Market Value, 2017-2026 ($ Million)

Figure 6 Global Periodontal Therapeutics Market Y-o-Y Growth, By Mechanism of Action, 2018-2026 (%)

Figure 7 Nucleotide Polymerase Inhibitors: Global Periodontal Therapeutics Market Value, 2017-2026 ($ Million)

Figure 8 Reverse Transcriptase Inhibitors: Global Periodontal Therapeutics Market Value, 2017-2026 ($ Million)

Figure 9 Protease Inhibitors: Global Periodontal Therapeutics Market Value, 2017-2026 ($ Million)

Figure 10 Others: Global Periodontal Therapeutics Market Value, 2017-2026 ($ Million)

Figure 11 Global Periodontal Therapeutics Market Y-o-Y Growth, By Application, 2018-2026 (%)

Figure 12 HIV: Global Periodontal Therapeutics Market Value, 2017-2026 ($ Million)

Figure 13 Hepatitis: Global Periodontal Therapeutics Market Value, 2017-2026 ($ Million)

Figure 14 Herpes Simplex Virus: Global Periodontal Therapeutics Market Value, 2017-2026 ($ Million)

Figure 15 Influenza: Global Periodontal Therapeutics Market Value, 2017-2026 ($ Million)

Figure 16 Others: Global Periodontal Therapeutics Market Value, 2017-2026 ($ Million)

Figure 17 Global Periodontal Therapeutics Market Y-o-Y Growth, By Distribution Channel, 2018-2026 (%)

Figure 18 Hospital Pharmacies: Global Periodontal Therapeutics Market Value, 2017-2026 ($ Million)

Figure 19 Retail Pharmacies: Global Periodontal Therapeutics Market Value, 2017-2026 ($ Million)

Figure 20 E-commerce: Global Periodontal Therapeutics Market Value, 2017-2026 ($ Million)

Figure 21 Global Periodontal Therapeutics Market Y-o-Y Growth, By Region, 2018-2026 (%)

Figure 22 North America Periodontal Therapeutics Market Value, 2017-2026 ($ Million)

Figure 23 North America Periodontal Therapeutics Market Share, By Mechanism of Action, 2018 & 2026 (%)

Figure 24 North America Periodontal Therapeutics Market Share, By Country, 2018 & 2026 (%)

Figure 25 South America Periodontal Therapeutics Market Value, 2017-2026 ($ Million)

Figure 26 South America Periodontal Therapeutics Market Share, By Distribution Channel, 2018 & 2026 (%)

Figure 27 South America Periodontal Therapeutics Market Share, By Country, 2018 & 2026 (%)

Figure 28 Europe Periodontal Therapeutics Market Value, 2017-2026 ($ Million)

Figure 29 Europe Periodontal Therapeutics Market Share, By Mechanism of Action, 2018 & 2026 (%)

Figure 30 Europe Periodontal Therapeutics Market Share, By Application, 2018 & 2026 (%)

Figure 31 Europe Periodontal Therapeutics Market Share, By Distribution Channel, 2018 & 2026 (%)

Figure 32 Europe Periodontal Therapeutics Market Share, By Country, 2018 & 2026 (%)

Figure 33 Asia-Pacific Periodontal Therapeutics Market Value, 2017-2026 ($ Million)

Figure 34 Asia-Pacific Periodontal Therapeutics Market Share, By Mechanism of Action, 2018 & 2026 (%)

Figure 35 Asia-Pacific Periodontal Therapeutics Market Share, By Application, 2018 & 2026 (%)

Figure 36 Asia-Pacific Periodontal Therapeutics Market Share, By Distribution Channel, 2018 & 2026 (%)

Figure 37 Asia-Pacific Periodontal Therapeutics Market Share, By Country, 2018 & 2026 (%)

Figure 38 Middle East & Africa Periodontal Therapeutics Market Value, 2017-2026 ($ Million)

Figure 39 Middle East & Africa Periodontal Therapeutics Market Share, By Mechanism of Action, 2018 & 2026 (%)

Figure 40 Middle East & Africa Periodontal Therapeutics Market Share, By Application, 2018 & 2026 (%)

Figure 41 Middle East & Africa Periodontal Therapeutics Market Share, By Distribution Channel, 2018 & 2026 (%)

Figure 42 F. Hoffmann-La Roche: Financials

Figure 43 Gilead Sciences: Financials

Figure 44 GlaxoSmithKline: Financials

Figure 45 Bristol-Myers Squibb: Financials

Figure 46 Johnson & Johnson: Financials

Figure 47 Merck & Co.: Financials

Figure 48 AbbVie Inc.: Financials

Figure 49 Abbott Laboratories: Financials

Figure 50 AstraZeneca plc: Financials

Figure 51 Pfizer Inc.: Financials

Did not find what you were looking for?Every 7 out of 10 customers request tailored reports. Get yours today!
We collate your requirements.
Our global research team is put into action.
We deliver, and make sure your endeavour is a success!

Buy This Report



Get your FREE SAMPLE PROPOSAL with a single click!